- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01942811
BiNational Quit Using Drugs Intervention Trial (BiN-QUIT)
US-Mexico Binational Quit Using Drugs Intervention Trial (QUIT)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
US Sites: Inclusion Criteria
Patients
- Adult men and women 18 and older receiving care at the study clinics
- Will be living in the LA area for the next three months
- Have a phone number at which they can be reached for the next three months
- Has a primary care visit for themselves on the date of recruitment and enrollment
- Has a primary care visit with a regular clinic provider on the date of recruitment and enrollment
- English or Spanish-speaking
- Report of drug use in the previous 90 days (i.e., cocaine or amphetamines), and has an ASSIST score between 4 and 26 indicating 'at risk' drug use
- Accessible by telephone where they can be contacted over time during the study (to conduct follow-up health education phone calls)
- Able (not cognitively impaired) and willing to cooperate with data collection and research procedures, including 2 telephone counseling sessions and 2-week, 6-week, and 3-month follow-up assessments
- Planning to be in the Los Angeles area for the next 3 months so they can complete the study period
Clinicians • Regular staff primary care clinicians of our study clinics
Mexico Sites: Inclusion Criteria
Patients
- Adult men and women 18 and older receiving care at the study clinics
- Will be living in the Tijuana area for the next three months
- Have a phone number at which they can be reached for the next three months
- Has a primary care visit for themselves on the date of recruitment and enrollment
- Has a primary care visit with a regular clinic provider on the date of recruitment and enrollment
- Spanish-speaking
- Report of drug use in the previous 90 days (i.e., cocaine or amphetamines), and has an ASSIST score between 4 and 26 indicating 'at risk' drug use
- Accessible by telephone where they can be contacted over time during the study (to conduct follow-up health education phone calls)
- Able (not cognitively impaired) and willing to cooperate with data collection and research procedures, including 2 telephone counseling sessions and 2-week, 6-week, and 3-month follow-up assessments
- Planning to be in the Tijuana area for the next 3 months so they can complete the study period
Clinicians
• Regular staff primary care clinicians of our study clinics
Exclusion Criteria:
US Sites: Exclusion Criteria
Patients
- Pregnancy. Women who report being pregnant at the time of randomization will be excluded from participation. This latter exclusion criterion is based on the following reasons: (a) The interaction of drug use (in any amount) and fetal-maternal health is physiologically complex and beyond the scope of this proposed intervention. (b) Drug users who are pregnant are considered high-risk pregnancies and will likely be lost to follow-up during the study as they will be promptly referred by their primary care clinician to an obstetrician per usual clinic protocol. However, enrolled patients who become pregnant after the intervention will not be withdrawn. Their eventual exits from the study will be counted as drop-outs and will be included as "no change" in our "intent to treat" analysis. Finally, (c) a tailored brief intervention protocol for pregnant women may require more than simple clinician advice and a 2-session phone health education program. Such an intervention would be more effective if designed around the activities of prenatal care. Previous RCTs of problem alcohol use targeting healthy adults have excluded patients who are pregnant.8,9
- Homeless status. The clinics we have chosen have large numbers of homeless patients. Since this is a study on the general poverty population, we are asking homeless status in order to avoid over-sampling homeless patients. We will set a quota on number of homeless patients we can enroll without over-sampling these patients. If we reach this quota, we will apply homeless status as an exclusion criteria for subsequent subjects.
- Repeaters. Patients who have been screened or enrolled before will be asked a set of repeater questions. This includes a question on whether they have ever been involved in our UCLA study at the clinic before. We will also ask them a set of questions that combines aspects about the potential subject (mother's first name, father's first name, month and day of birth) that will screen them out if they screen again in the future.
- ASSIST Score: Drug Dependence. The RA will receive a message that the subject scored 27+ on all illicit drugs on the WHO ASSIST (i.e. indication of possible substance dependence/addiction). The RA will inform the patient that they are at risk for certain health behaviors and ask the patient if they want to disclose this information to their doctor. If they agree to disclose information to their doctor then we will fill out a letter informing the doctor of patient's dependence on specific drugs. We will also provide the patient with a list of local substance abuse treatment referrals. Please see Appendix A for copies of these referrals (Appendix A. Los Angeles County Substance Abuse Treatment Facilities).
- From Date of Screening Subject Enrolled in a Drug Treatment Facility. Subjects enrolled in a treatment program are excluded from the study. These subjects show commitment to the treatment program. Moreover, these program would serve as a competing intervention to ours, biasing the potential effect of our intervention.
Clinicians • No exclusion criteria apply to clinicians
Mexico Sites: Exclusion Criteria
Patients
- Pregnancy. Women who report being pregnant at the time of randomization will be excluded from participation. This latter exclusion criterion is based on the following reasons: (a) The interaction of drug use (in any amount) and fetal-maternal health is physiologically complex and beyond the scope of this proposed intervention. (b) Drug users who are pregnant are considered high-risk pregnancies and will likely be lost to follow-up during the study as they will be promptly referred by their primary care clinician to an obstetrician per usual clinic protocol. However, enrolled patients who become pregnant after the intervention will not be withdrawn. Their eventual exits from the study will be counted as drop-outs and will be included as "no change" in our "intent to treat" analysis. Finally, (c) a tailored brief intervention protocol for pregnant women may require more than simple clinician advice and a 2-session phone health education program. Such an intervention would be more effective if designed around the activities of prenatal care. Previous RCTs of problem alcohol use targeting healthy adults have excluded patients who are pregnant.
- Homeless status. The clinics we have chosen have large numbers of homeless patients. Since this is a study on the general poverty population, we are asking homeless status in order to avoid over-sampling homeless patients. We will set a quota on number of homeless patients we can enroll without over-sampling these patients. If we reach this quota, we will apply homeless status as an exclusion criteria for subsequent subjects.
- Repeaters. Patients who have been screened or enrolled before will be asked a set of repeater questions. This includes a question on whether they have ever been involved in the Living Well study at the clinic before. We will also ask them a set of questions that combines aspects about the potential subject (mother's first name, father's first name, month and day of birth) that will screen them out if they screen again in the future.
- ASSIST Score: Drug Dependence. The RA will receive a message that the subject scored 27+ on all illicit drugs on the WHO ASSIST (i.e. indication of possible substance dependence/addiction). The RA will inform the patient that they are at risk for certain health behaviors and ask the patient if they want to disclose this information to their doctor. If they agree to disclose information to their doctor then we will fill out a letter informing the doctor of patient's dependence on specific drugs. We will also provide the patient with a list of local substance abuse treatment referrals.
- From Date of Screening Subject Enrolled in a Drug Treatment Facility. Subjects enrolled in a treatment program are excluded from the study. These subjects show commitment to the treatment program. Moreover, these program would serve as a competing intervention to ours, biasing the potential effect of our intervention.
Clinicians
• No exclusion criteria apply to clinicians
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Intervention
The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
|
The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles.
The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
Andra namn:
|
Inget ingripande: Control
Usual care and a health education booklet and video on cancer prevention
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Change from Baseline Self-reported number of drug-free days at 3 months
Tidsram: Past 30 and 90 days
|
Past 30 and 90 days
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Lillian Gelberg, MD, MSPH, University of California, Los Angeles
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- BINAT 3P30DA027
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Drog användning
-
University of KonstanzAfrica Mental Health FoundationAvslutad
-
Astellas Pharma Europe B.V.AvslutadFriska ämnen | Farmakokinetik | Drug-Drug Interaction (DDI)Tyskland
-
Astellas Pharma Europe B.V.AvslutadFriska ämnen | Drug-Drug Interaction (DDI)Frankrike
-
Theravance BiopharmaAvslutad
-
Astellas Pharma Europe B.V.Medivation, Inc.AvslutadFriska ämnen | Drug-Drug Interaction (DDI) | Enzalutamids farmakokinetikTyskland
-
Astellas Pharma Europe B.V.AvslutadFriska ämnen | Drug-Drug Interaction (DDI)Storbritannien
-
The Netherlands Cancer InstituteHar inte rekryterat ännuDrug Adherence Marker
-
Astellas Pharma Europe B.V.AvslutadFriska ämnen | Farmakokinetik | Drug-Drug Interaction (DDI)Tyskland
-
Astellas Pharma Europe B.V.Cubist Pharmaceuticals LLCAvslutadFriska ämnen | Drug-Drug Interaction (DDI) | Intestinal absorption | Rosuvastatins farmakokinetik | Farmakokinetiken för FidaxomicinTyskland
-
Astellas Pharma Europe B.V.AvslutadFriska ämnen | Farmakokinetik | DDI (Drug-Drug Interaction)Tyskland
Kliniska prövningar på Quit Using Drugs Intervention Trial
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI)Avslutad
-
Insud PharmaKenya Medical Research Institute; Barcelona Institute for Global Health; European... och andra samarbetspartnersHar inte rekryterat ännuJordöverförda helminterGhana, Kenya
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); East Carolina UniversityAktiv, inte rekryterandeKolorektal cancerFörenta staterna
-
University of North Carolina, Chapel HillEast Carolina UniversityAnmälan via inbjudanAndningssvikt | Fetma, sjuklig | Ventilator-inducerad lungskadaFörenta staterna
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); Medical University of South Carolina och andra samarbetspartnersRekryteringDrog användningFörenta staterna
-
University College CorkUniversity Hospital, Ghent; University Hospital WaterfordRekryteringMultisjuklighet | PolyfarmaciBelgien, Irland